123 related articles for article (PubMed ID: 30024607)
21. Limited usefulness of the free-to-total prostate-specific antigen ratio for the diagnosis and staging of prostate cancer in Japanese men.
Sakai I; Harada K; Hara I; Eto H; Miyake H
Int J Clin Oncol; 2004 Feb; 9(1):64-7. PubMed ID: 15162829
[TBL] [Abstract][Full Text] [Related]
22. Evaluation of the diagnostic use of free prostate specific antigen/total prostate specific antigen ratio in detecting prostate cancer.
Iqbal N; Chaughtai N
J Pak Med Assoc; 2005 Aug; 55(8):318-20. PubMed ID: 16164156
[TBL] [Abstract][Full Text] [Related]
23. Predictors of prostate cancer on repeat prostatic biopsy in men with serum total prostate-specific antigen between 4.1 and 10 ng/mL.
Okegawa T; Kinjo M; Ohta M; Miura I; Horie S; Nutahara K; Higashihara E
Int J Urol; 2003 Apr; 10(4):201-6. PubMed ID: 12657099
[TBL] [Abstract][Full Text] [Related]
24. Clinical usefulness of free PSA fraction as an indicator of prostate cancer.
Filella X; Alcover J; Molina R; Giménez N; Rodríguez A; Jo J; Carretero P; Ballesta AM
Int J Cancer; 1995 Dec; 63(6):780-4. PubMed ID: 8847133
[TBL] [Abstract][Full Text] [Related]
25. Elevated prostate specific antigen and reduced 10-year survival among a cohort of Danish men consecutively referred from primary care to an urological department during 2005-2006.
Hillig T; Nielsen TK; Hansen SI; Nygaard AB; Sölétormos G
Scand J Clin Lab Invest; 2017 Feb; 77(1):27-35. PubMed ID: 27762145
[TBL] [Abstract][Full Text] [Related]
26. Increased discrimination between benign prostatic hyperplasia and prostate cancer with equimolar total prostate specific antigen measurement.
Onur R; Ilhan N; Orhan I; Ilhan N
World J Urol; 2003 May; 21(1):43-7. PubMed ID: 12756494
[TBL] [Abstract][Full Text] [Related]
27. Complexed prostate-specific antigen, complexed prostate-specific antigen density of total and transition zone, complexed/total prostate-specific antigen ratio, free-to-total prostate-specific antigen ratio, density of total and transition zone prostate-specific antigen: results of the prospective multicenter European trial.
Djavan B; Remzi M; Zlotta AR; Ravery V; Hammerer P; Reissigl A; Dobronski P; Kaisary A; Marberger M
Urology; 2002 Oct; 60(4 Suppl 1):4-9. PubMed ID: 12384156
[TBL] [Abstract][Full Text] [Related]
28. Ratio of free or complexed prostate-specific antigen (PSA) to total PSA: which ratio improves differentiation between benign prostatic hyperplasia and prostate cancer?
Jung K; Elgeti U; Lein M; Brux B; Sinha P; Rudolph B; Hauptmann S; Schnorr D; Loening SA
Clin Chem; 2000 Jan; 46(1):55-62. PubMed ID: 10620572
[TBL] [Abstract][Full Text] [Related]
29. Total PSA, free PSA/total PSA ratio, and molecular PSA detection in prostate cancer: which is clinically effective and when?
Basso D; Fogar P; Piva MG; Navaglia F; Mazza S; Prayer-Galetti T; Castellucci E; Pagano F; Plebani M
Urology; 2000 May; 55(5):710-5. PubMed ID: 10792086
[TBL] [Abstract][Full Text] [Related]
30. Comparison of several combinations of free, complexed, and total PSA in the diagnosis of prostate cancer in patients with urologic symptoms.
Filella X; Truan D; Alcover J; Quintó L; Molina R; Luque P; Coca F; Ballesta AM
Urology; 2004 Jun; 63(6):1100-3; discussion 1103-4. PubMed ID: 15183958
[TBL] [Abstract][Full Text] [Related]
31. Prostate cancer antigen 3 test for prostate biopsy decision: a systematic review and meta analysis.
Luo Y; Gou X; Huang P; Mou C
Chin Med J (Engl); 2014; 127(9):1768-74. PubMed ID: 24791889
[TBL] [Abstract][Full Text] [Related]
32. Molecular forms of prostate-specific antigen in serum with concentrations of total prostate-specific antigen <4 microg/L: are they useful tools for early detection and screening of prostate cancer?
Jung K; Stephan C; Elgeti U; Lein M; Brux B; Kristiansen G; Rudolph B; Hauptmann S; Schnorr D; Loening SA; Sinha P
Int J Cancer; 2001 Sep; 93(5):759-65. PubMed ID: 11477592
[TBL] [Abstract][Full Text] [Related]
33. [New challenges and earlier approved methods in the laboratory diagnosis of prostate cancer].
Kovács GL
Magy Onkol; 2014 Dec; 58(4):301-9. PubMed ID: 25517448
[TBL] [Abstract][Full Text] [Related]
34. Comparative study of total prostate specific antigen and free to total prostate specific antigen ratio in the diagnosis of prostate cancer.
Chakraborty L; Ahmed AN; Paul BK; Haque A; Ara A; Nabi S; Nessa M
Mymensingh Med J; 2012 Jan; 21(1):98-102. PubMed ID: 22314462
[TBL] [Abstract][Full Text] [Related]
35. Serum total and free prostate-specific antigen for breast cancer diagnosis in women.
Black MH; Giai M; Ponzone R; Sismondi P; Yu H; Diamandis EP
Clin Cancer Res; 2000 Feb; 6(2):467-73. PubMed ID: 10690525
[TBL] [Abstract][Full Text] [Related]
36. Influence of free-to-total prostate specific antigen variability on the early diagnosis of prostate cancer: a comparative study of three immunoassays.
de la Taille A; Houlgatte A; Houdelette P; Goluboff ET; Berlizot P; Ricordel I
Br J Urol; 1998 Sep; 82(3):389-92. PubMed ID: 9772876
[TBL] [Abstract][Full Text] [Related]
37. Contemporary use of complexed PSA and calculated percent free PSA for early detection of prostate cancer: impact of changing disease demographics.
Miller MC; O'Dowd GJ; Partin AW; Veltri RW
Urology; 2001 Jun; 57(6):1105-11. PubMed ID: 11377319
[TBL] [Abstract][Full Text] [Related]
38. Determination of alpha1-antichymotrypsin-PSA complex in serum does not improve the differentiation between benign prostatic hyperplasia and prostate cancer compared with total PSA and percent free PSA.
Jung K; Brux B; Lein M; Knäbich A; Sinha P; Rudolph B; Schnorr D; Loening SA
Urology; 1999 Jun; 53(6):1160-7; discussion 1167-8. PubMed ID: 10367846
[TBL] [Abstract][Full Text] [Related]
39. Ratio of alpha 1-antichymotrypsin--prostate specific antigen to total prostate specific antigen in prostate cancer diagnosis.
Lein M; Jung K; Elgeti U; Brux B; Sinha P; Schnorr D; Loening SA
Anticancer Res; 2000; 20(6D):4997-5001. PubMed ID: 11326657
[TBL] [Abstract][Full Text] [Related]
40. Serum mucin antigens CASA and MSA in tumors of the breast, ovary, lung, pancreas, bladder, colon, and prostate. A blind trial with 420 patients.
Devine PL; McGuckin MA; Ramm LE; Ward BG; Pee D; Long S
Cancer; 1993 Sep; 72(6):2007-15. PubMed ID: 7689923
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
